Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of trastuzumab-MCC-DM1 vs trastuzumab + docetaxel in HER2-positive metastatic breast cancer
2008-002819-40Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2008
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab emtansine in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival (PFS). Started Sep 2008; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2008-002819-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002819-40.